63results about How to "Fast expression" patented technology

Pharmaceutical application of a chemodenervating agent, particularly botulinum toxin, reduces inflammatory response and serves as an anti-inflammatory agent without systemic side effects and with long duration action, on the order of 12-24 weeks. In one embodiment, the effective dosage for allergy provoked inflammation reduction is an order of magnitude less than dosages associated with treatment of regional movement diseases, since the agent works to reduce inflammation by reducing histamine and other preformed mediator releases associated with mast cell degranulation.

The invention discloses a text abstract generation method, an intelligent terminal and a storage medium, and the method comprises the steps: obtaining the input information of an abstract to be generated, and converting the input information into digital vector data; Inputting the digital vector data into a bidirectional recurrent neural network for operation through an encoder, and outputting sentences to a selection gate network to generate a new gate state sequence; Adding a Gaussian window to the gate state sequence output in the selection gate network through the attention layer, performing calculating to obtain a vector containing context information at the current moment, and outputting the vector to a decoder; And generating an output result with the highest prediction probabilitycorresponding to a real training result by decoding through a decoder, and taking the output result as the abstract of the input information. The text abstract is rapidly and accurately generated according to the requirements of the user, the purpose of accurately expressing the article can be achieved, the reading habit of the user is better met, and the user can rapidly obtain the main information of the article according to the text abstract.

The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing (1) an antacid, (2) an immediate-release part containing a compound unstable to acid and a basic substance, and (3) a sustained-release part containing a compound unstable to acid and a pH-independent material in combination.

The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucleotide and microparticles, with the microparticles being comprised of biodegradable polymer and cationic detergent. The dendritic cells and transfection agent are incubated for a time sufficient to transfect the dendritic cells with the polynucleotide.

The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing a combination of (1) an antacid, (2) an immediate-release part containing a compound unstable to acid and a basic substance, and (3) a sustained-release part containing a compound unstable to acid and a basic substance, and having a film that dissolves at pH 6.5 or above.

The invention discloses a method for simultaneously cloning multiple exogenous genes to a microbial genome. The method comprises steps of introducing a plurality of exogenous genes to a plurality of bidirectional gene expression carriers, and then simultaneously introducing the plurality of bidirectional gene expression carriers into a host microbe. Each bidirectional gene expression carrier comprises a bidirectional terminator and a bidirectional promoter. Except for the first bidirectional gene expression carrier and the last bidirectional gene expression carrier, the 3' ends of the bidirectional terminators of other bidirectional gene expression carriers and the 5' ends of the bidirectional terminators of the next bidirectional gene expression carriers have the same homologous arm. The 5' end of the bidirectional terminator of the first bidirectional gene expression carrier and the 3' end of the bidirectional terminator of the last bidirectional gene expression carrier can both carry out homologous recombination with the genomes of a host microbe. Through the provided method, established is a novel technology that can organically integrate the whole gene expression process such as expression design, clone design, host cell modification, and the like.

The present invention relates to methods and compositions for use in generating induced hepatocytes by reprogramming non-hepatocyte cells.

The present invention relates to a non-invasive diagnosis method of endometriosis by detecting biochemical marker in serum or peritoneal fluid, in particular alpha 1-antitrypsin, fragments of alpha 1-antitrypsin, or a combination of both. The diagnosis of endometriosis is performed with observing in serum specimens of a patient the concentration and change of the biochemical marker, in particular molecules related to alpha 1-antitrypsin, and comparing with a predetermined baseline level of the biochemical marker contained in serum. Statistical analysis can be performed to evaluate the baseline level indicating the occurrence of endometriosis. Therefore, the present invention can provide an auxiliary guideline for the diagnosis of endometriosis. The present invention also relates to usage of the biochemical marker.

The invention relates to a recombinant beta-glucosidase and an expression and purification method and the immobilization application thereof, and belongs to the technical field of biological enzyme engineering. The recombinant beta-glucosidase is recombinant beta-glucosidase Glu-linker-ELP-GB (GLEGB) obtained by linking binary labels ELP and GB with beta-glucosidase (Glu) through a universal linking peptide linker, wherein the sequence of GB polypeptide is linked to the 3' end of an ELP gene. By virtue of a reversible phase change property of an ELP label on recombinant enzyme, separation andpurification of the enzyme can be achieved; the recombinant enzyme containing the ELP label can be precipitated only by adding a certain amount of (HN4)2SO4 for incubation for a period of time; by virtue of a temperature response behavior of the ELP label, one-step rapid separation and purification of a target enzyme molecule is achieved; the enzyme purifying effect of the expression and purification method is superior to that of an ammonium sulfate precipitation method, and the purification cost of the expression and purification method is much lower than that of a chromatography method.

The present invention relates to non-aggregating VH domains or libraries thereof. The V_H domains comprise at least one disulfide linkage-forming cysteine in at least one complementarity-determining region (CDR) and an acidic isoelectric point (pI). A method of increasing the power or efficiency of selection of non-aggregating V_H domains comprises panning a phagemid-based V_H domain phage-display library in combination with a step of selecting non-aggregating phage-V_H domains. Compositions of matter comprising the non-aggregating V_H domains, as well as methods of use are also provided.

An imidazole compound represented by the formula (I), a salt thereof and a compound of the formula (V), which is one of the intermediates thereof. wherein each symbol is as defined in the present specification. The compound of the present invention shows a superior anti-ulcer activity, a gastric acid secretion inhibitory action, a mucosa-protecting action, an anti-Helicobacter pylori action and the like. Since it shows low toxicity, the compound is useful as a pharmaceutical product.

Sequences are provided that are capable of directing circular adeno-associated virus replication, useful in vectors for providing therapeutic agents to a subject in need thereof. The vectors of the invention are particularly useful in the treatment of acute medical conditions requiring rapid gene expression. Further provided are methods for producing packaged defective viral vectors.

The invention relates to a method for effectively reducing taxus media cell biosynthesis C-14 oxygenated taxane, which belongs to the technical field of genetic engineering. Through an meloidogynosis agrobacterium mediated binary vector transformation system, the method leads an antisense genetic expression vector constructed according to yew taxane 14Beta hydroxylase gene (referred to as 14OH) fragments into a Taxus media cultured cell. The method successfully obtains transgenic cells through an optimized transformation method. PCR-Southern hybridization, RT-PCR gene expression analysis and chemical component detection results have shown that the taxus media cell transgenic test succeeds, and the 14OH gen mRNA expression level in a transgenic cell system is significantly reduced. The method significantly inhibits the flowing of the taxus media cells to C-14 oxygenated taxoids, and is expected to lead metabolism to flow to C-13oxygenated taxoids including an anti-cancer drug taxol and the precursor baccatin III thereof, so as to provide a novel method for improving the biosynthesis yield of taxol.

The invention belongs to a field of biochemistry and molecular biology, and relates to a method used for rapidly identifying generation of recombinant virus particles in an eukaryotic expression. The method comprises using an eukaryotic expression vector Ac-Bacmid as a molecular carrier to construct an integrated recombinant bacmid for integratedly expressing egfp, wherein 120 bps at a 3' end of an ac68 gene of the molecular carrier is replaced by an egfp gene expression box and a tandem Cm expression box, transfecting the integrated recombinant bacmid to insect cells through mediation of liposome, and directly monitoring production situation of budding virus particles through visualization signals of green fluorescent. According to the invention, through observing the green fluorescent protein signals, whether the recombinant budding virus particles BV is generated in the transfected sf-9 insect cells can be rapidly determined, thereby further providing basis for expression of exogenous target genes transfected to the Ac-Bacmid and subsequent functional studies.

The invention discloses a method for downregulating micro RNA-126 expression, which is characterized in that a molecular biology technology is used, on a base of an eukaryotic vector containing a CMV promoter, an eukaryotic expression carrier containing miR-126-sponge is constructed, then RNA-126 expression is downregulated; the carrier enables in-vitro transfection to the eukaryotic cells, a fluorescence quantification PCR instrument is used for detecting the expression of a miR-126 mature form, and the biology effect after downregulating miR-126 expression can be observed through in-vitro experiment simultaneously. The method is capable of conveniently and rapidly downregulating miR-126 expression with long-acting, and can rapidly observe the biology effect after downregulating miR-126 expression. The method is adapted to cell transfection, and can be used for preparing the transgene animals.